211 results match your criteria: "Saiseikai Kumamoto Hospital Cardiovascular Center.[Affiliation]"
J Cardiol
December 2024
Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Background: Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) is a vital mechanical circulatory support for treating patients with refractory cardiogenic shock (CS). VA-ECMO can improve end-organ perfusion; however, it increases left ventricular (LV) afterload, resulting in further myocardial damage. ECPELLA, a combination of VA-ECMO and Impella (Abiomed Inc.
View Article and Find Full Text PDFCirc Cardiovasc Interv
December 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (K.H.).
Background: A small mitral valve area (MVA) is one of the challenging anatomies for transcatheter edge-to-edge repair (TEER) for mitral regurgitation, but the relationship between baseline MVA and clinical outcomes remains unknown. This study aimed to evaluate the association of baseline MVA with procedural and clinical outcomes in patients undergoing TEER with MitraClip from the OCEAN-Mitral registry (Optimized Catheter Valvular Intervention-Mitral).
Methods: A total of 1768 patients undergoing TEER were divided into 3 groups according to baseline MVA: group 1: <4.
Int J Cardiol
February 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
EuroIntervention
November 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Circ Rep
November 2024
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan.
Background: Data on the impact of valve position on clinical outcomes in patients with atrial fibrillation (AF) and bioprosthetic valves (BPVs) are limited.
Methods And Results: The BPV-AF Registry was a multicenter, prospective, observational study involving 894 patients with BPVs and AF. In this post-hoc substudy, patients were classified according to BPV position: aortic (n=588; 65.
Am J Cardiol
January 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Data concerning the clinical effect of the latest-generation self-expandable transcatheter heart valve (Evolut FX) remain limited. We aimed to assess the in-hospital outcomes of 3 bioprosthetic valves (Evolut EPO, PRO+, and FX). We analyzed data from a Japanese multicenter registry involving 634 consecutive patients who underwent transcatheter aortic valve replacement with Evolut FX up until October 2023.
View Article and Find Full Text PDFBackground: The Clinical Frailty Scale (CFS) is a useful frailty marker for predicting clinical outcomes in patients undergoing invasive therapy. However, the clinical impact of CFS after transcatheter edge-to-edge repair in patients with mitral regurgitation (MR) remains unclear. This study aimed to elucidate the association between the baseline frail status defined by the CFS and clinical outcomes with or without postprocedural MR ≥2+ (post-MR ≥2+) after transcatheter edge-to-edge repair.
View Article and Find Full Text PDFInt J Cardiol
January 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. Electronic address:
JACC Cardiovasc Interv
September 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
ESC Heart Fail
September 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Circ Rep
August 2024
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital Kobe Japan.
Circ Rep
August 2024
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine Mie Japan.
Background: Because the clinical benefit of antiplatelet therapy (APT) for patients with nonsignificant coronary artery disease (CAD) remains poorly understood, we evaluated it in patients after fractional flow reserve (FFR)-guided deferral of revascularization.
Methods And Results: From the J-CONFIRM (Long-Term Outcomes of Japanese Patients with Deferral of Coronary Intervention Based on Fractional Flow Reserve in Multicenter Registry), we investigated 265 patients with deferred lesions who did not require APT for secondary prevention of cardiovascular disease. A 2-year landmark analysis assessed the relationship between APT at 2 years and 5-year major cardiac adverse events (MACE: composite of all-cause death, target vessel-related myocardial infarction, clinically driven target vessel revascularization).
JACC Asia
July 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Int J Cardiol
October 2024
Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan. Electronic address:
JACC Cardiovasc Imaging
September 2024
McGovern Medical School, University of Texas Health Sciences Center, Houston, Texas, USA.
EuroIntervention
May 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
J Interv Card Electrophysiol
October 2024
Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Circ Cardiovasc Interv
June 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (K.H.).
Background: The extent of cardiac damage and its association with clinical outcomes in patients undergoing transcatheter edge-to-edge repair (TEER) for degenerative mitral regurgitation remains unclear. This study was aimed to investigate cardiac damage in patients with degenerative mitral regurgitation treated with TEER and its association with outcomes.
Methods: We analyzed patients with degenerative mitral regurgitation treated with TEER in the Optimized Catheter Valvular Intervention-Mitral registry, which is a prospective, multicenter observational data collection in Japan.
Cardiovasc Interv Ther
April 2024
Department of Medicine, Osaka Fukujuji Hospital, Neyagawa, Japan.
The relationship between sex differences and long-term outcomes after fractional flow reserve (FFR)- and instantaneous wave-free ratio (iFR)-guided deferral of revascularization has yet to be elucidated. From the J-CONFIRM registry (long-term outcomes of Japanese patients with deferral of coronary intervention based on FFR in a multicenter registry), this study included 432 lesions from 385 patients (men, 323 lesions in 286 patients; women, 109 lesions in 99 patients) with paired data of FFR and iFR. The primary endpoint was the cumulative 5-year incidence of target vessel failure (TVF), including cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization.
View Article and Find Full Text PDFJ Clin Med
February 2024
Department of Cardiology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
ESC Heart Fail
April 2024
Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Aims: Atrial fibrillation (AF) and heart failure (HF) often coexist. Older age is strongly associated with stroke, HF, and mortality. The association between coexistence of HF and a risk of clinical outcomes and the effectiveness of anticoagulation therapy including direct oral anticoagulants (DOACs) in elderly patients with AF and HF have not been investigated.
View Article and Find Full Text PDFCardiovasc Revasc Med
May 2024
Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Purpose: Mechanical circulatory support (MCS) using a venoarterial extracorporeal membrane oxygenation (VA-ECMO) device or a catheter-type heart pump (Impella) is critical for the rescue of patients with severe cardiogenic shock. However, these MCS devices require large-bore cannula access (14-Fr and larger) at the femoral artery or vein, which often requires surgical decannulation.
Methods: In this retrospective study, we evaluated post-closure method using a percutaneous suture-mediated vascular closure system, Perclose ProGlide/ProStyle (Abbott Vascular, Lake Bluff, IL, Perclose), as an alternative procedure for MCS decannulation.